RT Journal Article
SR Electronic
T1 Prognostic Imaging Biomarkers for Diabetic Kidney Disease (iBEAt): Study protocol
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.01.13.20017228
DO 10.1101/2020.01.13.20017228
A1 Kim M Gooding
A1 Chrysta Lienczewski
A1 Massimo Papale
A1 Niina Koivuviita
A1 Marlena Maziarz
A1 Anna-Maria Dutius Andersson
A1 Kanishka Sharma
A1 Paola Pontrelli
A1 Alberto Garcia Hernandez
A1 Julie Bailey
A1 Kay Tobin
A1 Virva Saunavaara
A1 Anna Zetterqvist
A1 David Shelley
A1 Irvin Teh
A1 Claire Ball
A1 Sapna Puppala
A1 Mark Ibberson
A1 Anil Karihaloo
A1 Kaj Metsärinne
A1 Rosamonde Banks
A1 Peter S Gilmour
A1 Michael Mansfield
A1 Mark Gilchrist
A1 Dick de Zeeuw
A1 Hiddo J.L. Heerspink
A1 Pirjo Nuutila
A1 Matthias Kretzler
A1 Matthew Wellberry-Smith
A1 Loreto Gesualdo
A1 Dennis Andress
A1 Nicolas Grenier
A1 Angela C Shore
A1 Maria F. Gomez
A1 Steven Sourbron
A1 iBEAt investigators
YR 2020
UL http://medrxiv.org/content/early/2020/01/16/2020.01.13.20017228.abstract
AB Diabetic kidney disease (DKD) is traditionally classified based on albuminuria and reduced kidney function (estimated glomerular filtration rate (eGFR)), but these have limitations as prognostic biomarkers due to the heterogeneity of DKD. Novel prognostic markers are needed to improve stratification of patients based on risk of disease progression.The iBEAT study, part of the BEAt-DKD consortium, aims to determine whether renal imaging biomarkers (magnetic resonance imaging (MRI) and ultrasound (US)) provide insight into the pathogenesis and heterogeneity of DKD (primary aim), and whether they have potential as prognostic biomarkers in DKD progression (secondary aim).iBEAT is a prospective multi-centre observational cohort study recruiting 500 patients with type 2 diabetes (T2D) and eGFR > 30ml/min/1.73m2. At baseline each participant will undergo quantitative renal MRI and US imaging with central processing for MRI images. Blood sampling, urine collection and clinical examinations will be performed and medical history obtained at baseline, and these assessments will be repeated annually for 3 years. Biological samples will be stored in a central laboratory for later biomarker and validation studies. All data will be stored in a central data depository. Data analysis will explore the potential associations between imaging biomarkers and renal function, and whether the imaging biomarkers may improve the prediction of DKD progression rates.Embedded within iBEAT are ancillary substudies that will (1) validate imaging biomarkers against renal histopathology; (2) validate MRI based renal blood flow against water-labelled positron-emission tomography (PET); (3) develop machine-learning methods for automated processing of renal MRI images; (4) examine longitudinal changes in imaging biomarkers; (5) examine whether the glycocalyx, microvascular function and structure are associated with imaging biomarkers and eGFR decline; (6) a pilot study to examine whether the findings in T2D can be extrapolated to type 1 diabetes.The iBEAT study, the largest DKD imaging study to date, will provide invaluable insights into the progression and heterogeneity of DKD, and aims to contribute to a more personalized approach to the management of DKD in patients with type 2 diabetes.Competing Interest StatementThis work forms part of the BEAt-DKD consortium that is funded by the Innovative Medicine Initiative (IMI). AMDA reports grants from Boehringer Ingelheim Pharma GmbH during the conduct of the study. AZ reports non-financial support and other from Boehringer Ingelheim Pharma GmbH during the conduct of the study. M Gilchrist reports personal fees from Lilly outside of the submitted work. DZ reports other from Fresenius, other from Boehringer Ingelheim, other from Bayer, other from Mitsubishi Tanabe, other from Mundipharma, other from Janssen, other from AbbVie, outside the submitted work. HJLH reports other from Merck, other from Mitsubishi Tanabe, grants and other from Janssen, other from Mundipharma, other from Gilead, grants and other from AstraZeneca, grants and other from Abbvie, other from Retrophin, outside the submitted work. MK reports grants from NIH, non-financial support from University of Michigan, during the conduct of the study; grants from JDRF, grants from Astra-Zeneca, grants from NovoNordisc, grants from Eli Lilly, grants from Gilead, grants from Goldfinch Bio, grants from Merck, grants from Janssen, grants from Boehringer-Ingelheim, outside the submitted work; In addition, MK has a patent Biomarkers for CKD progression (encompassing urinary EGF as biomarker of CKD progression) issued. DA reports other from AbbVie, outside the submitted work. M Gomez reports non-financial support and other from Boehringer Ingelheim Pharma GmbH, non-financial support and other from JDRF International, non-financial support and other from Eli Lilly, non-financial support and other from AbbVie, non-financial support and other from Sanofi-Aventis, non-financial support and other from Astellas, non-financial support and other from Novo Nordisk A/S, non-financial support and other from Bayer AG, during the conduct of the study; personal fees from Lilly, non-financial support and other from Novo Nordisk, non-financial support and other from Pfizer, non-financial support and other from Follicum, non-financial support and other from Abcentra, non-financial support from Probi, non-financial support from Johnson & Johnson, outside the submitted work. SS reports non-financial support from Siemens, during the conduct of the study.Clinical TrialNCT03716401Funding StatementThis project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115974. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA with JDRF.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesiBEAt investigators are committed to maximise the opportunities for data sharing at study completion in order to increase the lifetime value of their research data as assets for human health and to do so timely, responsibly, in a way consistent with the law, regulation and recognised good practice.